For instance, immune checkpoint blockade (ICB) therapy significantly elongates the survival of some treated cancer patients.[18] Immune checkpoint inhibitors restore the function of CTLs by blocking the immune checkpoints, allowing them to kill the tumor cells.[19] To date, the Food and Drug Administration (FDA) of USA has approved 5 antibody‐based immune checkpoint inhibitors, including pembrolizumab targeting PD‐1 and atezolizumab targeting PD‐L1. This evidence concerns the gene CD274 and cancer.